Key Highlights

  • Amplia Therapeutics has become one of the more closely followed clinical-stage biotechs on the ASX, and 2026 has given watchers plenty to
  • The defining program is the ACCENT trial, which has tested narmafotinib in combination with standard chemotherapy in advanced pancreatic cancer.
  • The most eye-catching development came on 4 August 2026, when Amplia announced a collaboration agreement with pharmaceutical major Eli Lilly to evaluate
  • Amplia has also been widening its clinical and intellectual-property base.

Amplia Therapeutics has become one of the more closely followed clinical-stage biotechs on the ASX, and 2026 has given watchers plenty to digest. The company is developing narmafotinib, a focal adhesion kinase (FAK) inhibitor, with its lead effort aimed at pancreatic cancer, one of the hardest tumours to treat. After a stream of trial, partnering and pipeline announcements through the year, the question for investors is which of several potential catalysts could re-rate the story next.

The defining program is the ACCENT trial, which has tested narmafotinib in combination with standard chemotherapy in advanced pancreatic cancer. Amplia presented mature ACCENT data at the American Association for Cancer Research conference in April 2026, and in May 2026 it moved to launch a Phase 2b, registration-enabling study of narmafotinib. Progressing from an early-phase signal to a registration-enabling design is a significant step for a company of Amplia's size, because it defines the pathway that could eventually support approval.

A partnering validation

The most eye-catching development came on 4 August 2026, when Amplia announced a collaboration agreement with pharmaceutical major Eli Lilly to evaluate narmafotinib combined with a KRAS G12C inhibitor in lung cancer. Collaborations with large partners are often read as external validation of a mechanism, and this one broadens narmafotinib's potential beyond pancreatic cancer into KRAS-driven tumours. In June 2026 the company had already written to shareholders outlining the rationale for combining FAK inhibition with KRAS inhibition, so the Lilly agreement built on a stated strategic direction rather than emerging from nowhere.

Amplia has also been widening its clinical and intellectual-property base. In May 2026 it announced an ovarian cancer study in collaboration with the ANZGOG cancer trials group, in July 2026 a new FAK inhibitor Patent application was published, and a scientific paper detailing narmafotinib's preclinical pancreatic cancer work was published late in July. The board was refreshed in early July with Leadership changes and the appointment of Brett Carter.

Financial position and scale

Amplia remains a small, pre-profit biotech. As at late August 2026 it carried a Market Capitalisation of roughly $74 million with about 513 million shares on issue, and it reported trailing Revenue of around $4.8 million against a net loss of about $7.7 million. The shares traded near 14.5 cents, within a 52-week range of 10.0 to 27.5 cents, underscoring how volatile sentiment can be for a single-asset-led clinical company.

For a Business at this stage, funding is a perennial consideration. Advancing a Phase 2b registration-enabling trial and supporting additional studies is expensive, and investors should assume the company will need to manage its cash runway carefully and may return to the market to fund the expanded program.

Why it matters and what to watch

The appeal is straightforward: a differentiated mechanism, a lead indication with enormous unmet need, a partnering nod from a global pharmaceutical company, and a broadening pipeline across pancreatic, ovarian and lung cancers. The risks are equally stark. Pancreatic cancer trials have a long history of disappointment, early-phase signals do not always survive larger controlled studies, and a small biotech is exposed to both clinical and financing risk.

The catalysts to watch are clear. Progress and eventual read-outs from the Phase 2b narmafotinib study are the central event. Beyond that, the direction of the Eli Lilly lung-cancer collaboration, updates from the ANZGOG ovarian study, and any funding announcements will shape the narrative. Amplia has assembled an unusually busy slate of programs for its size, but as with any clinical-stage biotech, the value ultimately hinges on the data rather than the news flow around it.